Holen Sie sich die Stockscreener-App
71.80
2.72%
-2.01
Handel nachbörslich:
71.80
Tarsus Pharmaceuticals Inc Aktie (TARS) Neueste Nachrichten
Tarsus to receive $15M milestone after China approves TP-03 eye therapy - MSN
Tarsus Pharmaceuticals: Marketing Spend Bears Fruit, Pipeline Progresses (NASDAQ:TARS) - Seeking Alpha
Published on: 2026-04-13 13:14:16 - baoquankhu1.vn
(TARS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Published on: 2026-04-08 15:20:10 - baoquankhu1.vn
Aug Rallies: Can Tarsus Pharmaceuticals Inc benefit from deglobalization2026 Update & Stepwise Trade Signal Guides - baoquankhu1.vn
Analyst Calls: Is Tarsus Pharmaceuticals Inc still a buy after recent gains2026 Market Trends & Low Risk High Reward Ideas - baoquankhu1.vn
Capricorn Fund Managers Ltd Decreases Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
The Bull Case For Tarsus Pharmaceuticals (TARS) Could Change Following First Dosing In TP-05 Lyme Trial - Sahm
Tarsus Pharmaceuticals, Inc. (TARS) stock price, news, quote and history - Yahoo Finance UK
Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded to Buy at Wall Street Zen - MarketBeat
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Moves And Ongoing Losses - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Alterity Therapeutics (OtherPRNAF), Tarsus Pharmaceuticals (TARS) and enGene Holdings (ENGN) - The Globe and Mail
JPMorgan Chase & Co. Sells 63,420 Shares of Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
A Look At Tarsus Pharmaceuticals (TARS) Valuation After TP-05 Phase 2 Lyme Disease Trial Begins - Sahm
How TP-05’s Phase 2 Lyme Prophylaxis Trial Progress Could Impact Tarsus Pharmaceuticals (TARS) Investors - Yahoo Finance
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $90 - Moomoo
Price-Driven Insight from (TARS) for Rule-Based Strategy - Stock Traders Daily
TARS Technical Analysis & Stock Price Forecast - Intellectia AI
Tarsus Pharmaceuticals (TARS) Initiates Phase 2 Trial for Lyme D - GuruFocus
Tarsus Pharmaceuticals, Inc. recently disclosed the latest progress on its leading vaccine candidate under development for Lyme disease. - Bitget
Biopharmaceutical company Tarsus Pharmaceuticals, Inc. announced that its innovative oral tablet TP-05 (lotilaner) for the potential prevention of Lyme disease has dosed the first subject in the Phase 2 clinical trial "Calliope". - Bitget
Tarsus Doses First Participant in Calliope, A Phase 2 - GlobeNewswire
First patient dosed in 700-person study to prevent Lyme disease - Stock Titan
Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Published on: 2026-03-30 08:36:12 - baoquankhu1.vn
How China TP-03 Approval and US$15 Million Milestone Could Shape Tarsus Pharmaceuticals (TARS) Investors - Sahm
Vanguard Realignment: Tarsus (NASDAQ: TARS) Ownership Reported as 0% by Parent - Stock Titan
Analysts Conflicted on These Healthcare Names: Cibus (CBUS), Arrowhead Pharmaceuticals (ARWR) and Tarsus Pharmaceuticals (TARS) - The Globe and Mail
Q2 EPS Estimate for Tarsus Pharmaceuticals Lifted by Analyst - MarketBeat
Mizuho raises Tarsus Pharmaceuticals stock price target on China approval By Investing.com - Investing.com Canada
Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Assenagon Asset Management S.A. - marketbeat.com
Can Tarsus Pharmaceuticals Inc maintain sales growth2026 Setups & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade - AOL.com
Tarsus Pharmaceuticals (TARS) COO sells 2,989 shares in planned trade - Stock Titan
Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade - The Motley Fool
Tarsus earns $15M milestone on China approval of eye drug By Investing.com - Investing.com South Africa
Tarsus earns $15M milestone on China approval of eye drug - Investing.com Canada
William Blair reiterates Outperform on Tarsus Pharmaceuticals stock By Investing.com - Investing.com Canada
Tarsus Pharmaceuticals shares rise on China drug approval milestone By Investing.com - Investing.com Canada
Tarsus Pharmaceuticals (TARS) Reaches $15M Milestone After TP-03 Approval in China - GuruFocus
Tarsus Pharmaceuticals Achieves $15 Million Milestone Payment Following Regulatory Approval of TP-03 in China - Quiver Quantitative
China clears first Demodex blepharitis treatment for 40 million people - Stock Titan
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus - Bitget
LifeSci Capital Remains a Buy on Tarsus Pharmaceuticals (TARS) - The Globe and Mail
TARS SEC FilingsTarsus Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
(TARS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Down 16.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Tarsus Pharmaceuticals (TARS) - msn.com
Seshadri Neervannan to sell TARS shares (NASDAQ: TARS) — March dispositions listed - Stock Titan
Tarsus Pharmaceuticals Insider Sold Shares Worth $2,364,904, According to a Recent SEC Filing - marketscreener.com
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):